The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

被引：101

作者：

Postel-Vinay, Sophie ^{[1
]}

Vanhecke, Elsa ^{[1
]}

Olaussen, Ken A. ^{[1
]}

Lord, Christopher J. ^{[2
]}

Ashworth, Alan ^{[2
]}

Soria, Jean-Charles ^{[1
]}

机构：

[1] Univ Paris 11, Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

[2] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2012年 / 9卷 / 03期

关键词：

MESSENGER-RNA EXPRESSION; DEPENDENT PROTEIN-KINASE; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MISMATCH-REPAIR; PROGNOSTIC-FACTOR; GEMCITABINE RESISTANCE; SYNTHETIC LETHALITY; ERCC1; EXPRESSION; GENE-EXPRESSION; CISPLATIN PLUS;

D O I：

10.1038/nrclinonc.2012.3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The tumor genome is commonly aberrant as a consequence of mutagenic insult and incomplete DNA repair. DNA repair as a therapeutic target has recently received considerable attention owing to the promise of drugs that target tumor-specific DNA-repair enzymes and potentiate conventional cytotoxic therapy through mechanism-based approaches, such as synthetic lethality. Treatment for non-small-cell lung cancer (NSCLC) consists mainly of platinum-based chemotherapy regimens and improvements are urgently needed. Optimizing treatment according to tumor status for DNA-repair biomarkers, such as ERCC1, BRCA1 or RRM1, could predict response to platinum, taxanes and gemcitabine-based therapies, respectively, and might improve substantially the response of individual patients' tumors. Finally, recent data on germline variation in DNA-repair genes may also be informative. Here, we discuss how a molecular and functional DNA-repair classification of NSCLC may aid clinical decision making and improve patient outcome.

引用

页码：144 / 155

页数：12

共 104 条

[1]

Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models [J].

Albert, Jeffrey M. ;

Cao, Carolyn ;

Kim, Kwang Woon ;

Willey, Christopher D. ;

Geng, Ling ;

Xiao, Dakai ;

Wang, Hong ;

Sandler, Alan ;

Johnson, David H. ;

Colevas, Alexander D. ;

Low, Jennifer ;

Rothenberg, Mace L. ;

Lu, Bo .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :3033-3042

[2]

Altaha R, 2004, INT J MOL MED, V14, P959

[3]

Reduced DNA-dependent protein kinase activity is associated with lung cancer [J].

Auckley, DH ;

Crowell, RE ;

Heaphy, ER ;

Stidley, CA ;

Lechner, JF ;

Gilliland, FD ;

Belinsky, SA .

CARCINOGENESIS, 2001, 22 (05) :723-727

[4]

XPG mRNA Expression Levels Modulate Prognosis in Resected Non-Small-Cell Lung Cancer in Conjunction with BRCA1 and ERCC1 Expression [J].

Bartolucci, Roberta ;

Wei, Jia ;

Sanchez, Jose Javier ;

Perez-Roca, Laia ;

Chaib, Imane ;

Puma, Francesco ;

Farabi, Raffaele ;

Mendez, Pedro ;

Roila, Fausto ;

Okamoto, Tatsuro ;

Taron, Miquel ;

Rosell, Rafael .

CLINICAL LUNG CANCER, 2009, 10 (01) :47-52

[5]

Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer [J].

Bepler, Gerold ;

Sommers, K. Eric ;

Cantor, Alan ;

Li, Xueli ;

Sharma, Anupama ;

Williams, Charles ;

Chiappori, Alberto ;

Haura, Eric ;

Antonia, Scott ;

Tanvetyanon, Tawee ;

Simon, George ;

Obasaju, Coleman ;

Robinson, Lary A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) :1112-1118

[6]

ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis [J].

Bepler, Gerold ;

Olaussen, Ken Andre ;

Vataire, Anne-Lise ;

Soria, Jean-Charles ;

Zheng, Zhong ;

Dunant, Ariane ;

Pignon, Jean-Pierre ;

Schell, Michael J. ;

Fouret, Pierre ;

Pirke, Robert ;

Filipits, Martin ;

Brambilla, Elisabeth .

AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (01) :69-78

[7]

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant [J].

Bergman, AM ;

Eijk, PP ;

van Haperen, VWTR ;

Smid, K ;

Veerman, G ;

Hubeek, I ;

van den Ijssel, P ;

Ylstra, B ;

Peters, GJ .

CANCER RESEARCH, 2005, 65 (20) :9510-9516

[8]

ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy [J].

Besse, B. ;

Massard, C. ;

Haddad, V. ;

Andre, F. ;

Dunant, A. ;

Pirker, R. ;

Olaussen, K. A. ;

Brambilla, E. ;

Fouret, P. ;

Soria, J. C. .

ANNALS OF ONCOLOGY, 2011, 22 (03) :575-581

[9]

Relative frequency and morphology of cancers in carriers of germline TP53 mutations [J].

Birch, JM ;

Alston, RD ;

McNally, RJQ ;

Evans, DGR ;

Kelsey, AM ;

Harris, M ;

Eden, OB ;

Varley, JM .

ONCOGENE, 2001, 20 (34) :4621-4628

[10]

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients [J].

Boukovinas, Ioannis ;

Papadaki, Chara ;

Mendez, Pedro ;

Taron, Miquel ;

Mavroudis, Dimitris ;

Koutsopoulos, Anastasios ;

Sanchez-Ronco, Maria ;

Javier Sanchez, Jose ;

Trypaki, Maria ;

Staphopoulos, Eustathios ;

Georgoulias, Vassilis ;

Rosell, Rafael ;

Souglakos, John .

PLOS ONE, 2008, 3 (11)

← 1 2 3 4 5 6 7 8 9 10 →